Disclosed are a novel pharmaceutical composition, a food or beverage, and methods for these products. The pharmaceutical composition is characterized by comprising the following protein (I) or (II) as an active ingredient: (I) a macrophage apoptosis inhibitor: and (II) a protein which comprises an amino acid sequence produced by deleting, substituting or adding one or several amino acid residues in the amino acid sequence for the macrophage apoptosis inhibitor and having homology with the aforementioned amino acid sequence, and has a function of inhibiting the differentiation of a progenitor adipocyte into a mature adipocyte and/or a function of inducing the decomposition of fat droplets in a mature adipocyte. For example, the pharmaceutical composition contains, as an active ingredient, a protein comprising an amino acid sequence depicted in sequence table 1, a protein comprising an amino acid sequence depicted in sequence table 5, or a mutant protein of any one of the aforementioned proteins which is so mutated that a function of inhibiting the differentiation of a progenitor adipocyte into a mature adipocyte and/or a function of inducing the decomposition of fat droplets in a mature adipocyte cannot be impaired.

Pharmaceutical composition, food or beverage, and methods for these products

A pharmaceutical composition including, as an active ingredient, one of the following proteins (I) and (II): (I) an apoptosis inhibitor of macrophage; and (II) a protein which consists of an amino acid sequence having deletion, substitution, or addition of one or more amino acids in an amino acid sequence of the apoptosis inhibitor of macrophage and having homology to the amino acid sequence of the apoptosis inhibitor of macrophage, and has a function of inhibiting the differentiation of preadipocytes to mature adipocytes and/or a function of inducing lipolysis in the mature adipocytes.

Methods of decreasing adipose tissue

The present invention relates to a method for treatment or prevention of a hemorrhagic condition in a patient by administering plasminogen activator inhibitor-1 (“PAI-1”) and/or an inhibitor of deubiquitinating enzyme CYLD (“CYLD”) to a patient. Pharmaceutical compositions that include one or both of PAI-1 and an inhibitor of CYLD are also disclosed.

Methods for the treatment or prevention of hemorrhagic conditions

The invention provides a novel gene and protein regulating the expression of Bacillus anthracis Anthrolysin O toxin, pharmaceutical compositions and antibodies which may be utilized for human or veterinary applications or for agricultural applications, and methods of treatment using same.

Regulation of gene expression by the Bacillus anthracis ARP

Methods for activating Toll-like receptor 4 via cholesterol-dependent cytolysins isolated from a Gram-positive bacteria are provided. In addition compositions containing an isolated cholesterol-dependent cytolysin or a fragment thereof or a mimetic of the cytolysin or fragment thereof and methods for use of such composition in inhibiting binding and/or interaction of Toll-like receptor 4 with endotoxin are provided. Methods for identifying modulators of Toll-like receptor 4 activation by a cholesterol-dependent cytolysin and use of such modulators in treatment of septicemia and/or septic shock are also provided.

Compositions and Methods for Activating Toll-like Receptor 4

Compounds, methods for identifying compounds and methods for using compounds which modulate interaction of lethal factor and anthrolysin O in the treatment and prevention of anthrax diseases are provided.

Richard Rest

Papers

Compositions and Methods for Activating Toll-like Receptor 4

Compositions and methods for preventing and treating anthrax diseases